No as in Dr Marsala’s mouse study it specifically targets the sod1 gene mutation. There is a version for the C9orf72 mutation in the preclinical pipeline but this type of therapy needs a mutation to target
some other FALS research will help sporadic though as they are looking at pathways that are implicated in FALS and SALS